Richard Levy
Director/Board Member bei MADRIGAL PHARMACEUTICALS, INC.
Vermögen: 3 Mio $ am 31.03.2024
Aktive Positionen von Richard Levy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Director/Board Member | 11.08.2016 | - |
| Independent Dir/Board Member | 11.08.2016 | - | |
| KODIAK SCIENCES INC. | Director/Board Member | 18.07.2018 | - |
| Independent Dir/Board Member | 18.07.2018 | - | |
| KINIKSA PHARMACEUTICALS, LTD. | Director/Board Member | 04.03.2019 | - |
| Independent Dir/Board Member | 04.03.2019 | - | |
| PROTARA THERAPEUTICS, INC. | Director/Board Member | 01.12.2019 | - |
| Independent Dir/Board Member | 01.12.2019 | - | |
Gliknik, Inc.
 Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Director/Board Member | 19.02.2014 | - |
Karriereverlauf von Richard Levy
Ehemalige bekannte Positionen von Richard Levy
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 03.04.2020 | 01.06.2021 |
| Independent Dir/Board Member | 03.04.2020 | 01.06.2021 | |
Aquinox Pharmaceuticals, Inc.
 Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Director/Board Member | 23.03.2017 | 08.08.2019 |
| Independent Dir/Board Member | 23.03.2017 | 08.08.2019 | |
| INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01.01.2009 | 30.04.2016 |
| Corporate Officer/Principal | 01.08.2003 | 01.01.2009 | |
| CELGENE | Corporate Officer/Principal | 01.01.2002 | 01.01.2003 |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░ ░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░ ░░░░░░ ░░░░░░ ░░ ░░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
Ausbildung von Richard Levy
| Brown University | Undergraduate Degree |
| University of Pennsylvania | Doctorate Degree |
| Perelman School of Medicine | Doctorate Degree |
Statistik
International
| Vereinigte Staaten | 16 |
| Kanada | 2 |
Operativ
| Director/Board Member | 8 |
| Independent Dir/Board Member | 6 |
| Corporate Officer/Principal | 4 |
Sektoral
| Health Technology | 13 |
| Consumer Services | 5 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 5 |
|---|---|
| INCYTE CORPORATION | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| KODIAK SCIENCES INC. | Health Technology |
| PROTARA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Gliknik, Inc.
Gliknik, Inc. Pharmaceuticals: MajorHealth Technology Gliknik, Inc. discovers and develops biotechnology drugs for autoimmune diseases and cancer. The company was founded by David S. Block and Scott E. Strome in 2007 and is headquartered in Baltimore, MD. | Health Technology |
DuPont Pharmaceuticals Co.
 DuPont Pharmaceuticals Co. Pharmaceuticals: MajorHealth Technology DuPont Pharmaceuticals Co. researches and develops pharmaceuticals and imaging products to treat diseases. It focuses on pharmaceuticals to treat unmet medical needs in the fight against HIV, cardiovascular disease, central nervous system disorders, cancer and arthritis-related disorders. The company is located in Wilmington, DE. | Health Technology |
Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. It also focuses on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. The company was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong, and Gerald Krystal on December 26, 2003 and is headquartered in Vancouver, Canada. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Sandoz Corp.
 Sandoz Corp. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Sandoz Corp. develops, produces, and markets medicines. | Health Technology |
ArTara Subsidiary, Inc.
 ArTara Subsidiary, Inc. Pharmaceuticals: MajorHealth Technology ArTara Subsidiary, Inc. engages in the research and development of specialty diseases therapeutics. Its programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology or gastrointestinal and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Richard Levy
- Erfahrung
